Physician profile
Paul E Emmans
NPI 1033130646
$2,794.74
in general payments reported to CMS, 2019-2025
10 companies · $748 in 2025
The $748 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $62.20 · 2021: $300 · 2022: $318 · 2023: $444 · 2024: $409 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $914.09 | 2019-2025 | Airsupra, Lokelma, Farxiga |
| Neurocrine Biosciences, INC. | $471.59 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $440.34 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $347.76 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $135.37 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $130.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.88 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $101.64 | 2023 | Aptiom |
| Glaxosmithkline, LLC. | $70.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Emmans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.